Vertex Pharmaceuticals Inc.

Core Business

Vertex Pharmaceuticals is a global biotechnology leader combining a dominant cystic fibrosis (CF) franchise with pioneering gene editing capabilities. Its CRISPR/Cas9 therapy CASGEVY represents the first approved treatment using gene editing technology, offering a potential cure for sickle cell disease and transfusion-dependent beta-thalassemia. In 2025, Vertex generated approximately $12 billion in total revenue, with CASGEVY contributing $116 million in its commercial ramp-up phase.

Global Presence

Headquartered in Boston, Massachusetts, Vertex operates in over 20 countries with 6,400 employees. Its CASGEVY authorized treatment center network spans the US, UK, Italy, UAE, Kuwait, and other major markets, with ongoing expansion plans. Vertex achieved 90% US insurance coverage for CASGEVY in 2025 — a remarkable market access achievement for a high-priced curative therapy.

Key Strengths

Vertex's unique position combining massive CF revenue generation with cutting-edge gene editing capabilities provides extraordinary strategic flexibility. The company's demonstrated ability to achieve broad insurance coverage for high-priced curative therapies represents a significant competitive advantage. Its active pipeline in type 1 diabetes stem cell therapy and pain management positions the company for long-term growth beyond CF and gene editing.

VerityRank Score

Vertex Pharmaceuticals achieves a VerityRank Score of 89/100, reflecting its pioneering CRISPR gene editing commercialization, exceptional market access capabilities, and robust financial foundation for continued CGT investment.

Vertex Pharmaceuticals combines a dominant cystic fibrosis franchise with pioneering CRISPR-based gene editing capabilities. Its Casgevy therapy is manufactured through strategic partnerships including Lonza's Geleen facility and a growing authorized treatment center network. The company actively invests in next-generation manufacturing approaches, including perfusion-based continuous processing.

• CRISPR/Cas9 gene-edited cell therapy for sickle cell disease and beta-thalassemia CASGEVY • Small molecule CFTR modulators for cystic fibrosis Trikafta/Kaftrio • Investigational stem cell-derived therapy for type 1 diabetes • Pain management therapeutics